AUTHORS
Ghada Araji, MD, Hana Qasim, Fellow2, Kriti Gera, MD3, Daniela Carolina Carolina Bravo Solarte, MD4, Melanie Jugl5, Jongphil Kim, PhD6, Rawan Faramand, MD7, Farhad Khimani, MD8, Taiga Nishihori, MD9, Fabiana Perna, MD, PhD10, Sayeef Mirza, BS, MPH, MD11, Alaa Ali, MD12, Brahm Segal, MD13, Frederick L. Locke, MD14, Michael D. Jain, MD, PhD15, Nima Ghalehsari, MD16, Sameh Gaballa, MD17, Aleksandr Lazaryan, MD MPH PhD18
AFFILIATIONS
1 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
2 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
3 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
4 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
5 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
6 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
7 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
8 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
9 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
10 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
11 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
12 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
13 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
14 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
15 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
16 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
17 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
18 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
ABSTRACT
Background: CD19-directed chimeric antigen receptor T-cell therapy (CAR T) is highly effective for relapsed/refractory (r/r) follicular lymphoma (FL), although clinically meaningful heterogeneity in toxicity and durability of response persists across products and patient subgroups. Toxicity-free, progression-free survival at 6 months (TPFS6), a composite endpoint integrating severe toxicity and disease control, was recently shown to predict outcomes after CAR T therapy for large B-cell lymphoma (Saha, Lazaryan et al., BMT 2026), but has not been evaluated in FL.
Methods: We performed a retrospective analysis of 53 consecutive adults with r/r FL treated at Moffitt Cancer Center between 2018 and 2025 with axicabtagene ciloleucel (n=34), tisagenlecleucel (n=17), or lisocabtagene maraleucel (n=2). TPFS6 was defined as survival without grade ≥3 CRS, grade ≥3 ICANS, NRM, or disease progression/stable disease (PD/SD) during the first 6 months after CAR T infusion, with only the first qualifying event counted toward TPFS6 failure. Factors associated with TPFS6 were evaluated using logistic regression. Six-month landmark analysis examined associations between TPFS6 with subsequent PFS and OS.
Results: The median age was 66 years (range 49-79); 68% were male; 94% had classical FL grade 1–3A histology and 6% had grade 3B disease; 49% had high tumor burden by GELF criteria. Patients had received a median of 4 prior therapies (range 1-14), with 83% receiving ≥3 prior lines. Any-grade CRS occurred in 68% of patients (grade ≥3, 1.9%) and any-grade ICANS in 40% (grade ≥3, 19%). At 6 months, ORR and CR rates were 92% and 84%, respectively. With a median follow-up of 28.6 months, 2-year OS and PFS were 88.7% and 60.5%. TPFS6 was achieved in 66.0% (35/53; 95% CI, 52.6–77.3). Among TPFS6 failures (n=18), severe ICANS accounted for 56% of events, PD/SD for 44.4% of events, whereas severe CRS was rare (5.6%) and no NRM occurred. Patients who failed TPFS6 were more likely to have high tumor burden by GELF criteria (72% vs. 37%; p=0.021). High tumor burden was independently associated with TPFS6 failure (OR 4.40, 95% CI 1.34–16.4; p=0.019; adjusted OR 3.64, 95% CI 1.09–12.15; p=0.035). TPFS6 was not significantly associated with subsequent OS or PFS in landmark analyses; however, interpretation was limited by our cohort size, relatively few events, and predominantly non-lymphoma-related mortality (8 of 9 deaths). Exploratory comparisons between axi-cel (n=34) and tisa-cel (n=17) did not identify significant differences in TPFS6, toxicity profiles, response rates, PFS, or OS; however, these analyses were limited by small sample size and lack of statistical power.
Conclusions: TPFS6 was achieved in two-thirds of FL patients receiving commercial CD19 CAR T-cell therapy. Failure to achieve TPFS6 was driven primarily by severe ICANS and early disease control failure rather than CRS or NRM. High tumor burden by GELF criteria independently predicted TPFS6 failure, supporting further evaluation of TPFS6 as an early composite measure of treatment success and risk stratification in FL.
DISCLOSURES
Ghada Araji, MD: No relevant conflicts of interest to declare.